The partners will combine their unique capabilities to jointly develop, offer, and deliver integrated services in the Antibody-Drug Conjugates (ADC) segment for the global pharmaceutical and biotechnology industries.
Agreement advances new therapies through Engitix’s unique focus on the extracellular matrix (ECM).
An exclusive distribution agreement for Evonik Rexim amino acids strengthens Brenntag's role in the biopharma and API markets.
DCAT reports that FDA has selected seven companies for its new PreCheck Pilot Program, designed to encourage US-based drug manufacturing through earlier engagement and a more predictable regulatory path.
Olon has completed a major expansion at its Concord, Ohio facility, doubling production capacity and strengthening the site's role as a US manufacturing hub within its global development network.
Fujifilm Biotechnologies' Holly Springs, NC facility has been chosen as one of seven participants in the FDA's PreCheck Pilot Program, aimed at strengthening US pharmaceutical manufacturing and regulatory readiness.
Innexis plans to acquire the multi-user facility in Kundl, Tyrol, from Novartis.
Syngene International announced that Siddharth Mittal has assumed the role of Managing Director and Chief Executive Officer of the Company, effective 1 July 2026.
Russell Thomas, who has held senior roles at both organisations, takes on the joint CSO position as Symeres and Axxam push to offer clients a single pipeline spanning target screening to IND-ready drug candidates.
Rentschler Biopharma has appointed Torsten Woehr as Chief Executive Officer (CEO), effective August 1, 2026.
CDMO Adragos Pharma Kawagoe and Towa Pharmaceutical have agreed to a manufacturing partnership that will nearly triple solid-dosage capacity, shoring up Japan's fragile generics supply chain.
Lonza to expand payload-linker manufacturing capacity in Visp (CH) to support the rapidly growing antibody-drug conjugate (ADC) market.
Digital Innovation: a key driver of competitiveness and sustainability across the pharmaceutical industry.
Drug discovery generates enormous amounts of data, but turning it into meaningful insight is a major challenge.
Pharma 4.0 is high on every strategic agenda. Yet many struggle to turn digital ambitions into measurable results. Projects stall, systems don’t align, and valuable insights remain locked in fragmented data structures.
Smart Experimentation - why the combination of Design of Experiments and Bayesian Optimization with intuitive analytics is the most important productivity lever your R&D organization isn't using
Shorter development cycles and complex active ingredients are demanding integrated solutions. Guided by the principle "Together – from lab to production," Fette Compacting positions its R&D Solutions as a partnership.
How Artificial Intelligence is transforming the work of biotech and pharma companies.
Lonza and Antharis Therapeutics announced an exclusive, target-specific licensing agreement to develop novel dual-payload ADCs targeting gastrointestinal (GI) cancers.
Recipharm announced a multi-million-dollar investment in its US operations, strengthening its ability to support pharma and biotech companies with advanced sterile fill and finish services.
Chiesi Group has completed its acquisition of KalVista Pharmaceuticals, marking the Italian biopharmaceutical group's largest deal to date.
Siegfried has inaugurated a new large-scale API production facility at its German site in Minden.
GSK has agreed to acquire US clinical-stage oncology specialist Nuvalent for $10.6 billion, its largest deal in years, to accelerate entry into lung cancer and boost growth through the dolutegravir patent cliff.
Axplora is repositioning its Italian Farmabios site on high-potency APIs as UDCA production moves to its FDA-approved Vizag facility in India, consolidating supply and scaling for global demand.
A clear signal to Berlin: the pharmaceutical companies Eli Lilly and Boehringer Ingelheim are canceling planned investments in Germany.
Sygnature Discovery has partnered with AI firm DaltonTx to sharpen its drug discovery pipeline, bringing faster medicinal chemistry decisions and tighter data privacy to its CRO offering.
Northway Biotech is finalizing the Baltic region's most advanced cell therapy center — a 3,500 m² facility at Vilnius City Innovation Industrial Park, set to open Q3 2025.
Acquisition strengthens US peptide manufacturing capabilities and broadens global expertise in complex peptide APIs
Catalent partners with non-profit Elpida Therapeutics to support late-phase AAV manufacturing for a rare neurological gene therapy, securing exclusive rights across Elpida's broader AAV pipeline.
Alcami completes its acquisition of Tjoapack, creating a 1,400-strong CDMO with over one million square feet of operations across the US and the Netherlands, adding European packaging scale and QP release services.
Hongene Biotech delivers end-to-end CDMO services for SiranBio's dual-target siRNA hepatitis B candidate, from raw materials through cGMP manufacturing, highlighting its capabilities in oligonucleotide therapeutics.
Bristol Myers Squibb licenses Lonza's SYNtecan linker-payload platform to advance an undisclosed ADC target, with Lonza eligible for upfront payments, milestones and royalties on resulting products.
Piramal Pharma Solutions opens a new payload-linker suite in Michigan as part of a $90 million US investment plan, bolstering its ADC manufacturing capabilities across sites in Riverview and Lexington.
Eli Lilly adds $4.5 billion to its Indiana manufacturing programme, funding a new genetic medicine facility and expanded API capacity at Lebanon, taking its total US investment since 2020 past $50 billion.
Symeres, a transatlantic CRDMO for drug discovery and development, announced the appointment of Henning Steinhagen as Chief Executive Officer.
